Following the completion of the Novo Nordisk Study, NN1250-3561 - BEGINTM - A trial investigating the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus, Insulin Degludec (Tresiba) has been granted a paediatric license.

In 2012-2013 the ScotCRN node at the Royal Aberdeen Children's Hospital (Principal Investigator Dr Amalia Mayo) was a site for this international, multi-centre study and recruited 5 patients.  The team were thanked for their participation in the study in a letter from Mark Fitch, Head of Clinical Operations at Novo Nordisk.

Author: DH